Regulus Therapeutics Net Income
| RGLSDelisted Stock | USD 8.16 0.01 0.12% |
As of the 5th of March, Regulus Therapeutics holds the Semi Deviation of 1.47, risk adjusted performance of 0.1651, and Coefficient Of Variation of 483.31. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Regulus Therapeutics, as well as the relationship between them. Please check Regulus Therapeutics downside deviation, jensen alpha, as well as the relationship between the Jensen Alpha and downside variance to decide if Regulus Therapeutics is priced some-what accurately, providing market reflects its current price of 8.16 per share. Given that Regulus Therapeutics has jensen alpha of 3.54, we recommend you to check out Regulus Therapeutics's recent market performance to make sure the company can sustain itself at a future point.
Regulus Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Regulus Therapeutics' valuation are provided below:Regulus Therapeutics does not presently have any trending fundamental ratios for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Regulus |
Search Suggestions
| R | Ryder System | Company |
| RF-PC | Regions Financial | Company |
| RCS | Pimco Strategic Income | Fund |
| RB | ProShares Trust | ETF |
| RCI | Dow Jones Composite | Index |
| RSR | RSR | Cryptocurrency |
| R9900CAT3 | YARNO 7378 14 NOV 32 | Corporate Bond |
| RBUSD | Gasoline RBOB | Commodity |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
CompetitionBased on the recorded statements, Regulus Therapeutics reported net income of (46.36 Million). This is 113.58% lower than that of the Biotechnology sector and 166.18% lower than that of the Health Care industry. The net income for all United States stocks is 108.12% higher than that of the company.
Regulus Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Regulus Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Regulus Therapeutics could also be used in its relative valuation, which is a method of valuing Regulus Therapeutics by comparing valuation metrics of similar companies.Regulus Therapeutics is currently under evaluation in net income category among its peers.
Regulus Fundamentals
| Return On Equity | -0.54 | |||
| Return On Asset | -0.34 | |||
| Current Valuation | 500.99 M | |||
| Shares Outstanding | 69.23 M | |||
| Shares Owned By Insiders | 2.70 % | |||
| Shares Owned By Institutions | 82.87 % | |||
| Number Of Shares Shorted | 2.09 M | |||
| Price To Earning | (0.69) X | |||
| Price To Book | 8.19 X | |||
| Price To Sales | 7.43 X | |||
| Gross Profit | (36.15 M) | |||
| EBITDA | (45.85 M) | |||
| Net Income | (46.36 M) | |||
| Cash And Equivalents | 47.53 M | |||
| Cash Per Share | 3.25 X | |||
| Total Debt | 274 K | |||
| Debt To Equity | 0.17 % | |||
| Current Ratio | 8.82 X | |||
| Book Value Per Share | 1.04 X | |||
| Cash Flow From Operations | (41.67 M) | |||
| Short Ratio | 1.57 X | |||
| Earnings Per Share | (0.68) X | |||
| Price To Earnings To Growth | (0.04) X | |||
| Target Price | 7.0 | |||
| Number Of Employees | 34 | |||
| Beta | 0.37 | |||
| Market Capitalization | 564.95 M | |||
| Total Asset | 84.18 M | |||
| Retained Earnings | (559.57 M) | |||
| Working Capital | 74.85 M | |||
| Current Asset | 134.26 M | |||
| Current Liabilities | 12.63 M | |||
| Net Asset | 84.18 M |
About Regulus Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Regulus Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Regulus Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Regulus Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Other Consideration for investing in Regulus Stock
If you are still planning to invest in Regulus Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Regulus Therapeutics' history and understand the potential risks before investing.
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |